The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
melanoma is a bit more complicated it has m0 meaning no Mets but it also has M1 a m1b m1c C and m1d and within each of those it has a threshold for high and low lactate dehydrogenase or LDH so it's both a staging based on Imaging and biochemical
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
melanoma has a very funny staging system so in cancer we typically talk about something called the tnm staging system it is the standard way that cancers are staged T refers to the tumor size n refers to the lymph node status and M refers to the presence or absence of metastases and for most cancers it is a very simple system it is you know T is typically a number one two sometimes up to three and four n is typically 0 one or two and M is zero or one either there's no Mets or there are Mets so for example in coloral cancer um the T staging determines the depth in the colon wall that it went n is did it go to Mets and I think in Colon I maybe a little rusty on this I think colon has n01 or two depending on how many lymph nodes and then m0 did it go to anything beyond that like to the liver lung Etc or not melanoma is a bit more complicated it has m0 meaning no Mets but it also has M1A m1b M1 C and m1d and within each of those it has a threshold for high and low lactate dehydrogenase or LDH so it's both a staging based on Imaging and biochemical
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.